Cover Image

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered

Alberto Ortiz,1,2 Maria Dolores Sanchez-Niño1,2 1Department of Nephrology, IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autónoma de Madrid, 2Department of Nephrology, Instituto Reina Sofia de Investigación Nefrológica, Madrid, Spain We read with interest the report by Goláň et al on t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ortiz A (Author), Sanchez-Niño MD (Author)
Format:	Book
Published:	Dove Medical Press, 2015-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
by: Goláň L, et al.
Published: (2015)

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
by: Kazuya Tsuboi, et al.
Published: (2017)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
by: Goker-Alpan O, et al.
Published: (2016)

Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data
by: Feriozzi S, et al.
Published: (2024)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
by: Ramaswami U, et al.
Published: (2019)

Update on role of agalsidase alfa in management of Fabry disease
by: Uma Ramaswami
Published: (2011)

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
by: Parini R, et al.
Published: (2020)

Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis
by: A. D. Dornelles, et al.
Published: (2024)

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
by: Hughes D, et al.
Published: (2021)

Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
by: Lina Fiege, et al.
Published: (2023)

Enzyme replacement therapy: efficacy and limitations
by: Daniela Concolino, et al.
Published: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
by: Aryun Kim, et al.
Published: (2021)

Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis
by: Becky Mingyao Ma, et al.
Published: (2024)

Efficacy and safety of two dose regimens of rituximab for idiopathic membranous nephropathy
by: Zhi-hui Tu, et al.
Published: (2024)

Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology
by: Chanchala D. Kaddi, et al.
Published: (2018)

Dose selection for biological enzyme replacement therapy indicated for inborn errors of metabolism
by: Yuen Yi Hon, et al.
Published: (2023)

Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data
by: Simon Shohet, et al.
Published: (2024)

Safety and efficacy of a novel three-step anti-acne regimen formulated specifically for women
by: Timothy Falla, PhD, et al.
Published: (2020)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
by: André B. P. van Kuilenburg, et al.
Published: (2023)

EFFICACY AND SAFETY OF ENZYME REPLACEMENT THERAPY IN CHILDREN WITH MUCOPOLYSACCHARIDOSIS TYPE I, II, AND VI: A SINGLE-CENTER COHORT STUDY
by: Liliia A. Osipova, et al.
Published: (2018)

Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial
by: Pengfei Jin, et al.
Published: (2024)

Dose Effect of Poractant Alfa in Neonatal RDS: Analysis of Combined Data from Three Prospective Studies
by: Barbara Królak-Olejnik, et al.
Published: (2020)

Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
by: Nato D. Vashakmadze, et al.
Published: (2020)

PECULIARITIES OF REPLACEMENT ENZYME THERAPY IN CHILDREN WITH CYSTIC FIBROSIS: BENEFITS OF HIGH-TECH ENZYMES
by: O.I. Simonova, et al.
Published: (2011)

PECULIARITIES OF REPLACEMENT ENZYME THERAPY IN CHILDREN WITH CYSTIC FIBROSIS: BENEFITS OF HIGH-TECH ENZYMES
by: O.I. Simonova, et al.
Published: (2011)

Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium
by: Corrado Angelini
Published: (2021)

Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing regimen in Japan
by: Mira Namba, et al.
Published: (2023)

The Efficacy and Safety of Multiple Dose Regimens of Kudzu (Pueraria lobata) Root Extract on Bone and Cartilage Turnover and Menopausal Symptoms
by: Asger Reinstrup Bihlet, et al.
Published: (2021)

Lysosomal acid lipase deficiency: analysis of enzyme replacement therapy
by: N.A. Polyanskaya, et al.
Published: (2022)

The Efﬁcacy and Safety of a Single Dose of Clindesse™ Vaginal Cream Versus a Seven-Dose Regimen of Cleocin® Vaginal Cream in Patients With Bacterial Vaginosis
by: Sebastian Faro, et al.
Published: (2005)

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
by: Wang X, et al.
Published: (2013)

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
by: A. N. Meshkov
Published: (2016)

Evaluation of immunogenicity, safety and breakthrough following administration of live attenuated varicella vaccine in two doses three months apart regimen in Indian children
by: Monjori Mitra, et al.
Published: (2020)

Dental effects of enzyme replacement therapy in case of childhood-type hypophosphatasia
by: Rena Okawa, et al.
Published: (2021)

Enzyme replacement therapy for Fabry disease: some answers but more questions
by: Majid Alfadhel, et al.
Published: (2011)

Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
by: Specchio N, et al.
Published: (2020)

Cognitive Outcome of Infants with Pompe Disease Receiving Enzyme-Replacement Therapy
by: J Gordon Millichap
Published: (2012)

Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2021)

The COVID-19 Pandemic and Enzyme Replacement Therapy in Lysosomal Storage Disorders
by: Asburçe Olgaç, et al.
Published: (2021)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
by: Qian Li, et al.
Published: (2023)